Clinical Trial Update: A Phase 3 Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) [Phase 3]

View source ↗

Summary

This Phase 3 long-term extension study, ENSEMBLE, aims to assess the long-term safety and efficacy of pegTibatinase in participants aged 5 to 65 with classical …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homocystinuria

Drugs mentioned

• Pegtibatinase (pegtibatinase)

Snippet

Sponsor: Travere Therapeutics, Inc. | Conditions: Homocystinuria | Phase 3 | Status: ENROLLING_BY_INVITATION